Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Withdrawn 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Somatostatinoma 1Prostatic Neoplasms 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Growth Hormone-Secreting Pituitary Adenoma 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1

Interventions

Trastuzumab 303Paclitaxel 256Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Doxorubicin 145Fulvestrant 144Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 88Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 44Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Complementary Therapies × Clear all
NCT00003455 2013-07-10

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT00003536 2013-07-10

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡